Seres Therapeutics (NASDAQ:MCRB) Stock Crosses Below Fifty Day Moving Average – Here’s What Happened

Seres Therapeutics, Inc. (NASDAQ:MCRB) shares passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $0.91 and traded as low as $0.79. Seres Therapeutics shares last traded at $0.84, with a volume of 1,948,018 shares changing hands.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on MCRB. Chardan Capital reiterated a “buy” rating and issued a $1.25 price objective on shares of Seres Therapeutics in a research report on Wednesday, August 14th. Canaccord Genuity Group reiterated a “buy” rating and set a $10.00 price target on shares of Seres Therapeutics in a research report on Friday, September 13th. Finally, StockNews.com lowered shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 13th.

Seres Therapeutics Price Performance

The stock has a market cap of $126.60 million, a price-to-earnings ratio of -1.39 and a beta of 2.03. The firm has a 50 day simple moving average of $0.91 and a two-hundred day simple moving average of $0.91.

Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.08. During the same period in the prior year, the firm earned $0.36 earnings per share. On average, sell-side analysts expect that Seres Therapeutics, Inc. will post -0.95 earnings per share for the current fiscal year.

Insider Transactions at Seres Therapeutics

In related news, insider Teresa L. Young sold 24,480 shares of the company’s stock in a transaction on Monday, August 5th. The shares were sold at an average price of $1.08, for a total value of $26,438.40. Following the completion of the sale, the insider now owns 78,178 shares in the company, valued at $84,432.24. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 28,844 shares of company stock valued at $30,104 over the last three months. 5.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Seres Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Seres Therapeutics during the 1st quarter worth approximately $39,000. Vanguard Group Inc. raised its holdings in shares of Seres Therapeutics by 12.1% during the first quarter. Vanguard Group Inc. now owns 6,734,821 shares of the biotechnology company’s stock worth $5,213,000 after acquiring an additional 729,514 shares during the period. Virtu Financial LLC bought a new stake in Seres Therapeutics in the 1st quarter valued at $73,000. Providence Wealth Advisors LLC boosted its stake in Seres Therapeutics by 49.5% in the 2nd quarter. Providence Wealth Advisors LLC now owns 76,250 shares of the biotechnology company’s stock worth $58,000 after purchasing an additional 25,250 shares during the period. Finally, Point72 DIFC Ltd bought a new position in Seres Therapeutics during the 2nd quarter worth about $64,000. 59.34% of the stock is currently owned by institutional investors and hedge funds.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.